FOSUN PHARMA recommends spinning off FOSUN Antengene to independently list on the main board
FOSUN PHARMA (02196.HK) announced the proposal to spin off the group's vaccine business platform company - FOSUN ANTIGEN and list it on the Hong Kong Stock Exchange. This issuance is planned to be conducted globally, with an initial scale not exceeding 25% of the expanded total share capital. The proposed spin-off listing is subject to meeting several conditions, including obtaining shareholder approval, completing the filing with the China Securities Regulatory Commission, and obtaining approvals from the Hong Kong Stock Exchange and other relevant departments
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments